{"id":"W4393121545","doi":"10.1177/17562864241239453","title":"Comparative efficacy of ofatumumab <i>versus</i> oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVERSANA (Canada)","funders":"Novartis Australia","keywords":"Fingolimod; Medicine; Cladribine; Ofatumumab; Teriflunomide; Placebo; Internal medicine; Multiple sclerosis; Natalizumab; Disease; Alternative medicine; Immunology; Rituximab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05043303,0.001303388,0.003298084,0.001505932,0.0003370286,0.002052426,0.001462417,0.001473649,0.004107527],"category_scores_gemma":[0.05560048,0.0005225121,0.01254543,0.001108343,0.001154282,0.001288679,0.001509872,0.002181888,0.0002597076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001440205,"about_ca_system_score_gemma":0.001721195,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001944999,"about_ca_topic_score_gemma":0.0009624844,"domain_scores_codex":[0.9710166,0.02479375,0.001135629,0.001740161,0.0008020154,0.0005117168],"domain_scores_gemma":[0.9196898,0.06835546,0.006932793,0.003151674,0.00100062,0.0008696853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2016043,0.002756893,0.1132037,0.00364877,0.1221155,0.0002858286,0.0004120307,0.4688013,0.001414756,0.01314842,0.002348025,0.0702605],"study_design_scores_gemma":[0.04090226,0.05439764,0.05822275,0.0006144277,0.06755833,0.0002940271,0.0003032072,0.7408465,0.002512826,0.03016633,0.003909384,0.0002724011],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9416654,0.006648742,0.04183644,0.0009476457,0.0002849932,0.002359421,0.003160232,0.0001270607,0.002970147],"genre_scores_gemma":[0.990965,0.0005756083,0.005955874,0.0001752073,0.00006297856,0.0009605269,0.0009712224,0.00001075755,0.0003228411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05043303,"threshold_uncertainty_score":0.2667185,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3913923956294829,"score_gpt":0.4403275504441665,"score_spread":0.04893515481468363,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}